Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

539 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.
Hargrave DR, Terashima K, Hara J, Kordes UR, Upadhyaya SA, Sahm F, Bouffet E, Packer RJ, Witt O, Sandalic L, Kieloch A, Russo M, Cohen KJ; Investigators involved in the high-grade glioma cohort. Hargrave DR, et al. Among authors: hara j. J Clin Oncol. 2023 Nov 20;41(33):5174-5183. doi: 10.1200/JCO.23.00558. Epub 2023 Aug 29. J Clin Oncol. 2023. PMID: 37643378 Clinical Trial.
Clinical characteristics, treatment, and survival outcome in pediatric patients with atypical teratoid/rhabdoid tumors: a retrospective study by the Japan Children's Cancer Group.
Yamasaki K, Kiyotani C, Terashima K, Watanabe Y, Kanamori M, Koga Y, Hata N, Iwasaki F, Goto H, Koh K, Kurihara J, Tokunaga S, Arakawa Y, Hasegawa D, Kosaka Y, Hara J. Yamasaki K, et al. Among authors: hara j. J Neurosurg Pediatr. 2019 Nov 15;25(2):111-120. doi: 10.3171/2019.9.PEDS19367. Print 2020 Feb 1. J Neurosurg Pediatr. 2019. PMID: 31731266
[Effectiveness of remission induction with high-dose cytarabine for relapsed or refractory pediatric acute leukemia].
Horikoshi Y, Kobayashi R, Endo M, Watanabe A, Kikuta A, Koike K, Hanada R, Hosoya R, Ohara A, Ikuta K, Goto H, Asami K, Sugita K, Horibe K, Tsurusawa M, Hori T, Hara J, Nishimura S, Nagatoshi Y, Mugishima H, Ohta S, Adachi S, Tsukimoto I. Horikoshi Y, et al. Among authors: hara j. Rinsho Ketsueki. 2010 Feb;51(2):104-13. Rinsho Ketsueki. 2010. PMID: 20379101 Clinical Trial. Japanese.
Correction to: Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).
Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H, Tajiri T, Nakagawara A; Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG). Hishiki T, et al. Among authors: hara j. Int J Clin Oncol. 2020 Sep;25(9):1744-1745. doi: 10.1007/s10147-020-01752-4. Int J Clin Oncol. 2020. PMID: 32749556
The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors.
Nakamura H, Takami H, Yanagisawa T, Kumabe T, Fujimaki T, Arakawa Y, Karasawa K, Terashima K, Yokoo H, Fukuoka K, Sonoda Y, Sakurada K, Mineharu Y, Soejima T, Fujii M, Shinojima N, Hara J, Yamasaki K, Fujimura J, Yamasaki F, Takahashi M, Suzuki T, Sato I, Nishikawa R, Sugiyama K. Nakamura H, et al. Among authors: hara j. Neuro Oncol. 2022 Apr 1;24(4):503-515. doi: 10.1093/neuonc/noab242. Neuro Oncol. 2022. PMID: 34671804 Free PMC article.
Outcome of children with relapsed high-risk neuroblastoma in Japan and analysis of the role of allogeneic hematopoietic stem cell transplantation.
Hara J, Nitani C, Shichino H, Kuroda T, Hishiki T, Soejima T, Mori T, Matsumoto K, Sasahara Y, Iehara T, Miyamura T, Kosaka Y, Takimoto T, Nakagawara A, Tajiri T; Japan Children’s Cancer Group (JCCG) Neuroblastoma Committee (JNBSG). Hara J, et al. Jpn J Clin Oncol. 2022 May 5;52(5):486-492. doi: 10.1093/jjco/hyac007. Jpn J Clin Oncol. 2022. PMID: 35137156
539 results